Skip to main content
Clinical Trials/DRKS00010872
DRKS00010872
Recruiting
Not Applicable

Prospective validation of the prognostic biomarker CD8+ TEMRA cells for disturbed fracture healing. - BioBone

Charité Universitätsmedizin Berlin / Berlin-Brandenburger Centrum für Regenerative Therapien / Julius Wolff Institut0 sites800 target enrollmentJuly 26, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
S82.1
Sponsor
Charité Universitätsmedizin Berlin / Berlin-Brandenburger Centrum für Regenerative Therapien / Julius Wolff Institut
Enrollment
800
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2016
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Charité Universitätsmedizin Berlin / Berlin-Brandenburger Centrum für Regenerative Therapien / Julius Wolff Institut

Eligibility Criteria

Inclusion Criteria

  • full Age (18\+),
  • contractually capable,
  • patient who understand the informed consent \+ signed consent,
  • fracture of the Long bones,
  • surgery Treatment \= osteosynthesis,
  • patient was mobilised before the fracture/surgery occured

Exclusion Criteria

  • periprothetic fractures,
  • pathological fractures,
  • active Tumor disease,
  • active Tumor therapy/Treatment,
  • HIV, Hepatitis B and/or C positive,
  • drug\-dependent person
  • psyschological disease,
  • pregnant or nursing Person,
  • participation in another, parallel running interventional study

Outcomes

Primary Outcomes

Not specified

Similar Trials